Results 51 to 60 of about 296,469 (371)

Sustained virological response in HIV/HCV co‐infected patients without rapid virological response (RVR) on peginterferon‐ribavirin therapy [PDF]

Journal of the International AIDS Society, 2010
7‐11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow ...
Labarga, P, Vispo, ME, Guardiola, JM, Miralles, C, Martín-Carbonero, L, Portu, J, Barreiro, P, Miralles, P, Morello, J, Tellez, MJ, Bancalero, P, Asensi, V, Rallón, NI, Santos, I, Morano, L, Aguirrebengoa, K, Rios, MJ, Rubio, R, Neukam, K, González-Lahoz, J, Soriano, V   +20 more
openaire   +1 more source

Safety of monitoring antiretroviral therapy response in HIV-1 infection using CD4+ T cell count at long-term intervals

Cadernos de Saúde Pública, 2018
: The latest Brazilian guideline recommended the reduction of routine CD4+ T cell counts for the monitoring of patients with human immunodeficiency virus type 1 (HIV-1) under combination antiretroviral therapy (cART).
Ingridt Hildegard Vogler, Daniela Frizon Alfieri, Heloisa Damazio Bruna Gianjacomo, Elaine Regina Delicato de Almeida, Edna Maria Vissoci Reiche   +4 more
doaj   +1 more source

Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution

Gut and Liver, 2021
Background/Aims: Glecaprevir/pibrentasvir (G/P) is a combination of direct-acting antiviral agents that is an approved treatment for chronic infections by all six hepatitis C virus (HCV) genotypes.
Young Joo Park, Hyun Young Woo, Jeong Heo, Sang Gyu Park, Young Mi Hong, Ki Tae Yoon, Dong Uk Kim, Gwang Ha Kim, Hyung Hoi Kim, Geun Am Song, Mong Cho   +10 more
doaj   +1 more source

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1 [PDF]

, 2019
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917). Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic ...
Ajana, F, Arribas, JR, Bailey, J, Benson, P, Berenguer, J, Bhatti, L, Blaxhult, A, Brar, I, Bredeek, UF, Brinson, C, Brown, Kimberley, Brunetta, J, Casado, J, Clarke, A, Conway, B, Cotte, L, Crofoot, G, Cunningham, D, Cunningham, Douglas, de Vente, J, De Wit, S, De Wit, Stéphane, DeJesus, E, Dietz, C, Dretler, R, Eron, J, Eron, Joseph J, Fehr, J, Felizarta, F, Fichtenbaum, C, Flamholc, L, Florence, E, Galindo, MJ, Gallant, J, Gasiorowski, J, Gatell, JM, Gathe, J, Gazzard, BG, Girardy, P-M, Gisslèn, M, Gutierrez, F, Gutierrez, MDM, Hagins, D, Halota, W, Henn, S, Henry, WK, Horban, A, Hufkens, Veerle, Huhn, G, Iribarren, JA, Jain, M, Jezorwski, John, Johnson, MA, Katlama, C, Klein, M, Knobel, H, Lathouwers, Erkki, Lucasti, C, Martorell, C, McDonald, C, Mills, A, Molina, J-M, Morales-Ramirez, J, Mounzer, K, Moutschen, M, Murphy, D, Nahass, R, Negredo, E, Olivet, H, Opsomer, Magda, Orkin, C, Orkin, Chloe, Osiyemi, O, Perez-Valero, I, Petrovic, Romana, Piekarska, A, Pineda, JA, Podzamczer, D, Poizot-Martin, I, Portilla Sogorb, J, Post, F, Post, Frank A, Prelutsky, D, Pulido, F, Pulido, Federico, Rachlis, A, Raffi, F, Ramgopal, M, Rashbaum, B, Rauch, A, Rey, D, Reynes, J, Ricart, C, Richmond, G, Rivero, A, Ruane, P, Santos Gil, I, Scarsella, A, Scribner, A, Shafran, S, Shalit, P, Shamblaw, D, Slim, J, Stoeckle, M, Tashima, K, Teicher, E, Thalme, A, Ustianowski, A, Van Landuyt, Erika, Van Wijngaerden, E, Vandekerckhove, Linos, Vandercam, B, Voskuhl, G, Walmsley, S, Ward, D, Waters, L, Wilkin, A, Witor, A, Yazdanpanah, Y   +118 more
core   +2 more sources

Effectiveness of direct-acting antiviral drugs against hepatitis C virus: predictive factors of response to the treatment

Libyan Journal of Medicine, 2021
Background/Aims. Despite the high efficacy and safety of direct-acting antivirals against hepatitis C virus shown in clinical trials, treatment failures continue to occur.
María E. Cárdaba-García, Encarnación Abad-Lecha, Miguel Á. Calleja-Hernández   +2 more
doaj   +1 more source

Meta‐analysis: insulin resistance and sustained virological response in hepatitis C [PDF]

Alimentary Pharmacology & Therapeutics, 2011
Aliment Pharmacol Ther 2011; 34: 297–305SummaryBackground  A higher baseline homeostasis model assessment of insulin resistance (HOMA‐IR) score has sometimes predicted a poorer sustained virological response (SVR) rate to peginterferon/ribavirin therapy in treatment‐naïve chronic hepatitis C patients.Aim  To perform a meta‐analysis to evaluate the ...
Eslam, Mohammed, Aparcero, Reyes, Kawaguchi, Takumi, del Campo, José A., Sata, Michio, Khattab, Mahmoud A, Romero-Gomez, Manuel   +6 more
openaire   +2 more sources

Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study

Metabolism Open, 2021
Background and aim: The incidence of hepatocellular carcinoma (HCC) decreases significantly in chronic hepatitis C (CHC) patients with sustained virologic response (SVR) after pegylated-interferon plus ribavirin (PR) or direct-acting antiviral (DAAs ...
Dong Ji, Guo-feng Chen, Xiao-xia Niu, Mingjie Zhang, Cheng Wang, Qing Shao, Vanessa Wu, Yudong Wang, Gregory Cheng, Selwyn J. Hurwitz, Raymond F. Schinazi, George Lau   +11 more
doaj   +1 more source

Predictive Factors for Sustained Remission after Discontinuation of Antiviral Therapy in Patients with HBeAg-positive Chronic Hepatitis B

The Korean Journal of Gastroenterology, 2016
Background : /Aims: The optimal timing for discontinuing oral antiviral therapy in patients with HBeAg-positive chronic hepatitis B (CHB) is unclear. The aim of our study was to investigate sustained remission after stopping antiviral therapy in patients
Baek Gyu Jun, Sae Hwan Lee, Hong Soo Kim, Sang Gyune Kim, Young Seok Kim, Boo Sung Kim, Soung Won Jeong, Jae Young Jang, Young Don Kim, Gab Jin Cheon   +9 more
doaj   +1 more source

Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting. [PDF]

, 2011
In resource-limited settings, many patients, with no prior protease inhibitor (PI) treatment on a second-line, high genetic barrier, ritonavir-boosted PI-containing regimen have virologic ...
Arribas, Bangsberg, Barreiro, Berg, Carolina Malavazzi, Cassani, Delaugerre, El-Khatib, Eric Decloedt, Frost, Gandhi, Gardner, Gary Maartens, Gathe, Gert Uves van Zyl, Helen McIlleron, Huang, Jean B Nachega, Kosuge, Lize van der Merwe, Michele Zeier, Mo, Monica Gandhi, Peter Smith, Pujades-Rodriguez, Quiros-Roldan, Riddler, Thijs E van Mens, van Zyl, van Zyl, Yong Huang   +30 more
core   +3 more sources

Sustained virological response according to the type of early virological response in HCV and HCV/HIV

Annals of Hepatology, 2010
The most important factors to predict the sustained virological response (SVR) are the genotype and the fibrosis grade, although there are other predictive factors to be considered, mainly in HCV/HIV coinfected patients.To evaluate different prognostic factors to obtain the SVR in HCV monoinfected and HCV/HIV coinfected genotype 1 patients emphasizing ...
Paulo R. Lerias de Almeida, Angelo Alves de Mattos, Cristiane Valle Tovo   +2 more
openaire   +3 more sources